Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Multiple Sclerosis

Free Subscription 01.03.2021 4 J Neurol 1 J Neurol Sci 1 JAMA 6 Mult Scler 1 Rev Neurol 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

J Neurol

1. BUCELLO S, Annovazzi P, Ragonese P, Altieri M, et al
   Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
   J Neurol. 2021 Feb 22. pii: 10.1007/s00415-021-10455.
   PubMed         Abstract available
   
   
2. WALZL D, Solomon AJ, Stone J
   Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.
   J Neurol. 2021 Feb 21. pii: 10.1007/s00415-021-10436.
   PubMed         Abstract available
   
   
3. CAPONE F, Ferraro E, Motolese F, Di Lazzaro V, et al
   COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
   J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10446.
   PubMed        
   
   
4. FILIPPI M, Capra R, Centonze D, Gasperini C, et al
   Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.
   J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10466.
   PubMed        
   
   

   
   J Neurol Sci

5. EILAM-STOCK T, Shaw MT, Krupp LB, Charvet LE, et al
   Early neuropsychological markers of cognitive involvement in multiple sclerosis.
   J Neurol Sci. 2021;423:117349.
   PubMed         Abstract available
   
   

   
   JAMA

6. MCGINLEY MP, Goldschmidt CH, Rae-Grant AD
   Diagnosis and Treatment of Multiple Sclerosis: A Review.
   JAMA. 2021;325:765-779.
   PubMed         Abstract available
   
   

   
   Mult Scler

7. AMATO MP, Portaccio E, De Meo E
   Understanding the pathophysiology of cognitive changes in MS: A step forward.
   Mult Scler. 2021;27:4-5.
   PubMed        
   
   
8. COPETTI M, Liu D
   Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
   Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
   PubMed        
   
   
9. FOX RJ, Raska P, Barro C, Karafa M, et al
   Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
   Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
   PubMed         Abstract available
   
   
10. AL-ARAJI S, Ciccarelli O
    A possible case of serum sickness after ocrelizumab infusion - Commentary.
    Mult Scler. 2021;27:158-159.
    PubMed         Abstract available
    
    
11. SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
    Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
    PubMed         Abstract available
    
    
12. BISTROM M, Hultdin J, Sundstrom P
    Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
    Mult Scler. 2021;27:161-162.
    PubMed        
    
    

    
    Rev Neurol

13. BENITO-VILLALVILLA D, Lopez de Uralde-Villanueva I, Rios-Leon M, Alvarez-Melcon AC, et al
    [Effectiveness of motor imagery in patients with multiple sclerosis: a systematic review].
    Rev Neurol. 2021;72:157-167.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

14. JOUBERT M, Paris P, Clavelou P, Moisset X, et al
    Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: A case report.
    Rev Neurol (Paris). 2021 Feb 19. pii: S0035-3787(21)00032.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: